In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Invacare onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:IVCR.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2022	742	-101	-59	-55	N/A
9/30/2022	787	-79	-31	-24	N/A
6/30/2022	840	-67	-17	-5	N/A
3/31/2022	877	-56	-44	-28	N/A
12/31/2021	872	-46	-32	-14	N/A
9/30/2021	870	-53	-36	-16	N/A
6/30/2021	858	-37	-31	-11	N/A
3/31/2021	828	-43	-6	18	N/A
12/31/2020	851	-28	0	22	N/A
9/30/2020	860	-42	-12	8	N/A
6/30/2020	883	-43	2	19	N/A
3/31/2020	923	-39	4	15	N/A
12/31/2019	928	-53	-8	3	N/A
9/30/2019	940	-36	-11	-2	N/A
6/30/2019	948	-40	-29	-19	N/A
3/31/2019	959	-44	-54	-44	N/A
12/31/2018	972	-44	-56	-46	N/A
9/30/2018	978	-60	-37	-22	N/A
6/30/2018	984	-67	-36	-22	N/A
3/31/2018	972	-74	-34	-20	N/A
12/31/2017	966	-77	-40	-26	N/A
9/30/2017	963	-77	-71	-61	N/A
6/30/2017	980	-63	-65	-53	N/A
3/31/2017	1,022	-51	-60	-48	N/A
12/31/2016	1,047	-43	-67	-57	N/A
9/30/2016	1,084	-28	N/A	-19	N/A
6/30/2016	1,100	-31	N/A	-24	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if IVCR.Q's forecast earnings growth is above the savings rate (2.1%).

Winst versus markt: Insufficient data to determine if IVCR.Q's earnings are forecast to grow faster than the US market

Hoge groeiwinsten: Insufficient data to determine if IVCR.Q's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if IVCR.Q's revenue is forecast to grow faster than the US market.

Hoge groei-inkomsten: Insufficient data to determine if IVCR.Q's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if IVCR.Q's Return on Equity is forecast to be high in 3 years time

Invacare Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased to US$1.65

Consensus EPS estimates fall by 77%

Price target decreased to US$4.27

Consensus EPS estimates fall by 43%

Invacare Corporation Reaffirms Revenue Guidance for the Full Year 2022

Price target decreased to US$6.25

Recent updates

Invacare Corporation announced delayed 10-Q filing

Silverback Asset Management Engages with Invacare Corporation

Invacare Corporation announced delayed annual 10-K filing

Invacare Corporation announced delayed 10-Q filing

Invacare Corporation Enters Settlement Agreement with Sunrise Medical (Us) Llc and Sunrise Medical Gmbh

Invacare Holdings Corporation Announces Executive Changes

Invacare Corporation(OTCPK:IVCR.Q) dropped from S&P TMI Index

NYSE to Suspend Trading Immediately in Invacare Corporation and Commence Delisting Proceedings

Invacare Corporation Filed for Bankruptcy

Invacare falls on bankruptcy filing

Invacare Corporation Filed for Bankruptcy

Invacare announces additional draw of $5.5M term loans

Invacare Corporation Appoints Geoffrey P. Purtill as President

Price target decreased to US$1.65

Invacare Corporation (NYSE:IVC) Analysts Just Slashed Next Year's Estimates

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Invacare GAAP EPS of -$0.92, revenue of $170.4M

Invacare Corporation to Report Q3, 2022 Results on Nov 07, 2022

Invacare Corporation Receives Notice of Noncompliance with NYSE Trading Share Price Listing Rule

Invacare receives non-compliance letter from NYSE

Invacare Corporation Announces Executive Changes

Invacare names Geoffrey Purtill as interim president and executive chief

Invacare Corporation Announces Board and Committee Appointments

Invacare adds two new directors after deal with largest investor Azurite

Consensus EPS estimates fall by 77%

Price target decreased to US$4.27

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Invacare Corporation to Report Q2, 2022 Results on Aug 08, 2022

Invacare Corporation(NYSE:IVC) dropped from Russell 2000 Value Index

Invacare Corporation Introduces the Birdie Evo Xplus Patient Lift to the U.S. Market

Invacare Corporation Introduces the Birdie Evo Xplus Patient Lift to the U.S. Market

Consensus EPS estimates fall by 43%

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Invacare Corporation Reaffirms Revenue Guidance for the Full Year 2022

Returns Are Gaining Momentum At Invacare (NYSE:IVC)

Price target decreased to US$6.25

Invacare Corporation to Report Q1, 2022 Results on May 09, 2022

Invacare Corporation, Annual General Meeting, May 19, 2022

Consensus EPS estimates fall by 148%

Price target decreased to US$7.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Invacare Corporation to Report Q4, 2021 Results on Mar 08, 2022

Invacare Corporation Introduces Its Next Generation E-Fix Eco Power Assist Device to Transform the Manual Wheelchair

Invacare Corporation Introduces New, Narrow Version of Invacare® AVIVA® STORM RX™ Rear Wheel Drive Power Wheelchair

Invacare (NYSE:IVC) Use Of Debt Could Be Considered Risky

Invacare Announces New Features in LiNX® 3 Electronics

Senior VP & GM of EMEA Ralf Ledda has left the company

Returns On Capital Are Showing Encouraging Signs At Invacare (NYSE:IVC)

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.65 loss per share (vs US$0.21 loss in 3Q 2020)

Here's Why Invacare (NYSE:IVC) Is Weighed Down By Its Debt Load

Price target decreased to US$11.33

Invacare Corporation Provides Sales Guidance for the Third Quarter and Full Year 2021

Independent Director Baiju Shah has left the company

Independent Director recently sold US$59k worth of stock

Consensus forecasts updated

When Should You Buy Invacare Corporation (NYSE:IVC)?

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.48 loss in 2Q 2020)

Invacare Corporation Introduces the Invacare® AVIVA STORM RX, a Next Generation Rear Wheel Drive Power Wheelchair

Increases to CEO Compensation Might Be Put On Hold For Now at Invacare Corporation (NYSE:IVC)

Consensus EPS estimates fall to -US$0.56

First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.022 profit in 1Q 2020)

Invacare Corporation Reaffirms Earnings Guidance for the Full Year 2021

Invacare EPS misses by $0.02, misses on revenue

Returns On Capital Are Showing Encouraging Signs At Invacare (NYSE:IVC)

Full year 2020 earnings released: US$0.82 loss per share (vs US$1.59 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Invacare Corporation's (NYSE:IVC) Path To Profitability

Invacare Corporation and Its Subsidiary, Alber Usa, LLC Introduces the Next Generation Alber E-Motion® Power Assist Device